Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.
On Thursday, Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab) subcutaneous formulation via an on-body delivery system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback